Zhou Jin, Sinha Rohit A, Yen Paul M
Program of Cardiovascular and Metabolic Disorders, Duke-NUS Medical School, Singapore 169857, Singapore.
Department of Endocrinology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India.
Hepatoma Res. 2021 Nov 5;7:72. doi: 10.20517/2394-5079.2021.82. eCollection 2021.
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disorder worldwide. It comprises simple steatosis and non-alcoholic steatohepatitis (NASH), which can further progress to cirrhosis and hepatocellular carcinoma. The pathogenesis of NAFLD involves genetic, environmental, and endocrine factors, and several molecular mechanisms have been identified. In this review, we discuss the recent findings on the role of autophagy, in particular lipophagy and mitophagy, in hepatic lipid oxidation. We discuss the pre-clinical and clinical evidence suggesting that impairment of autophagy exacerbates NAFLD progression and restoration of autophagy exerts beneficial effects on NAFLD. We discuss how thyroid hormone (TH) simultaneously regulates lipophagy, mitophagy, and mitochondrial biogenesis to increase β-oxidation of fatty acids and reduce steatosis in the liver. Lastly, we discuss the recent clinical progress in using TH or thyromimetics in treating NAFLD/NASH.
非酒精性脂肪性肝病(NAFLD)是全球最普遍的慢性肝脏疾病。它包括单纯性脂肪变性和非酒精性脂肪性肝炎(NASH),后者可进一步发展为肝硬化和肝细胞癌。NAFLD的发病机制涉及遗传、环境和内分泌因素,并且已经确定了几种分子机制。在本综述中,我们讨论了自噬,特别是脂质自噬和线粒体自噬在肝脏脂质氧化中的作用的最新发现。我们讨论了临床前和临床证据,这些证据表明自噬受损会加剧NAFLD的进展,而自噬的恢复对NAFLD具有有益作用。我们讨论了甲状腺激素(TH)如何同时调节脂质自噬、线粒体自噬和线粒体生物发生,以增加脂肪酸的β-氧化并减少肝脏中的脂肪变性。最后,我们讨论了使用TH或甲状腺激素类似物治疗NAFLD/NASH的最新临床进展。